Neoadjuvant sacituzumab govitecan for muscle-invasive bladder cancer

Antonio Cigliola, MD, IRCCS San Raffaele Hospital, Milan, Italy, provides insight into the potential widespread use of neoadjuvant sacituzumab govitecan (SG) in the clinic for treating patients with muscle-invasive bladder cancer (MIBC), who are unwilling or ineligible for cisplatin-based chemotherapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.